A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

Inclusion Criteria: * If female of childbearing potential, is not pregnant (confirmed by negative urine pregnancy test) or lactating and must have used reliable birth control measures throughout the study. * At least a 2-year reliable medical history consistent with SAR * Positive skin test within 12 months of screening to at least one seasonal allergen present in the geographical area * Capable of tolerating intranasal application of the IMP, willing and able to comply with the requirements of the protocol * No clinically significant findings in physical and nasal examinations, and medical history. * A reflective TNSS of at least 6 (out of 12) in the 24 hours prior to placebo lead-in visit. * Successfully complete the placebo lead-in period. Exclusion Criteria: * \- Signs or symptoms of nasal polyps, deviated septum, or any other condition which, in the opinion of the Investigator, could resulted in erroneous study data. * Undergo nasal surgery or had nasal trauma within 3 months of screening. * Active respiratory conditions or respiratory tract infection that require antibiotic treatment within 2 weeks of screening * Persistent allergic rhinitis (PAR) that does not require or not expected to require active PAR treatment during the study period. * Evidence of any unstable or clinically significant conditions that would place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives. * Presence or history of clinically significant conditions which in the opinion of the Investigator would have compromised the safety of the subject or the conduct of the study. * Use of corticosteroids, intranasal cromolyn, Leukotriene inhibitors, long or short acting antihistamines, intranasal or systemic decongestants prior to the start of the single-blind, placebo lead-in visit within the time periods specified in the protocol or receiving immunotherapy. * Use of an investigational drug within 30 days before screening or during the study. * Known or suspected hypersensitivity to corticosteroids. * Inability to avoid exposure to chicken pox or measles. * Infection requiring oral antibiotic treatment 2 weeks prior to screening. * Previously identified as a placebo responder or known as a non responder to corticosteroids. * History of alcohol, drug, or substance abuse in the 12 months prior to Visit 1 (screening). * Positive for hepatitis B or C, or human immunodeficiency virus (HIV). * Uncooperative or non compliant. * Female subjects who planned to become pregnant during the conduct of the study. * Current smoker (former smokers had to be 6 months smoke free).